Skip to content
Subscribe Follow on LinkedIn

Latest

Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility

Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility

✨ Onyx Summary Piramal Pharma Solutions announced the acquisition of a Korsch XM-12 bilayer tablet press for its Morpeth, UK facility, enhancing its capabilities in oral solid and hormonal drug product development and manufacturing. The investment strengthens precision, flexibility, and containment in tablet production, supporting Piramal’s commitment to advanced drug

SpyGlass Pharma Appoints Anand Sundaram as Head of Commercial

SpyGlass Pharma Appoints Anand Sundaram as Head of Commercial

✨ Onyx Summary SpyGlass Pharma appointed Anand Sundaram as Vice President, Head of Commercial, to lead launch strategy and build its commercial organization ahead of two planned Phase III trials for its sustained drug delivery platform. Sundaram brings extensive ophthalmic commercialization experience from Opthea, Iveric Bio, Novartis, and Genentech, strengthening SpyGlass’

2025 Eisai R&D Day: Deepening Connections

2025 Eisai R&D Day: Deepening Connections

✨ Onyx Summary MassBio will host the 2025 Eisai R&D Day on October 20 at Eisai’s G2D2 Center in Cambridge, featuring panel discussions, poster sessions, and networking to showcase Eisai’s R&D priorities in neuroscience, oncology, and global health. By fostering direct engagement between Eisai and

Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

✨ Onyx Summary Avidity Biosciences closed a $690 million public offering of 17.25 million shares at $40 each, including the full exercise of underwriters’ option to purchase additional shares. The proceeds will support late-stage clinical development of its Antibody Oligonucleotide Conjugates (AOCs), preparation for multiple product launches, expansion of commercial

Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

✨ Onyx Summary Perspective Therapeutics has dosed the first patient in a new Phase 1/2a cohort evaluating [212Pb]VMT01, its targeted alpha-particle therapy, in combination with Bristol Myers Squibb’s nivolumab (Opdivo®) for patients with metastatic melanoma. The expansion to a higher 3.0 mCi dose and combination arm marks

Alex M. Azar II Joins Guardant Health Board of Directors

Alex M. Azar II Joins Guardant Health Board of Directors

✨ Onyx Summary Guardant Health announced the appointment of former U.S. Health and Human Services Secretary Alex M. Azar II to its board of directors, bringing extensive leadership experience from both government and the private sector. His addition underscores Guardant’s ambition to pair policy expertise with scientific innovation, strengthening

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock

✨ Onyx Summary Avidity Biosciences priced an upsized public offering of 15 million shares at $40 each, expected to raise $600 million before expenses, with underwriters granted a 30-day option to purchase up to 2.25 million additional shares. Proceeds will be used to advance its three late-stage RNA therapeutic programs,

Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership

Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership

✨ Onyx Summary Guardant Health announced a strategic agreement with LabFlorida/SunDx Labs to make its FDA-approved Shield™ blood test for colorectal cancer screening available to residents of senior living communities across Florida. By extending Shield to this high-risk, underserved population, the partnership could transform preventive care in aging communities—removing